Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience

BACKGROUND: Adalimumab (Ada) treatment is an available option for pediatric Crohn’s disease (CD) and the published experience as rescue therapy is limited. OBJECTIVES: We investigated Ada efficacy in a retrospective, pediatric CD cohort who had failed previous infliximab treatment, with a minimum fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvisi, Patrizia, Arrigo, Serena, Cucchiara, Salvatore, Lionetti, Paolo, Miele, Erasmo, Romano, Claudio, Ravelli, Alberto, Knafelz, Daniela, Martelossi, Stefano, Guariso, Graziella, Accomando, Salvatore, Zuin, Giovanna, De Giacomo, Costantino, Balzani, Lucio, Gennari, Monia, Aloi, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322517/
https://www.ncbi.nlm.nih.gov/pubmed/30655661
http://dx.doi.org/10.2147/BTT.S183088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322517/
https://www.ncbi.nlm.nih.gov/pubmed/30655661
http://dx.doi.org/10.2147/BTT.S183088

Ejemplares similares